23
July
2015


Share on networks

  • AstraZeneca acquired the respiratory division of Almirall for 1.5 billion euros.
  • Barcelona is now home to one of the five AstraZeneca research centers in the world.  

British pharmaceutical company AstraZeneca, which acquired the respiratory disease division of Catalan company Almirall for 1.5 billion euros a few months ago, will invest 540 million euros between 2015 and 2017 to create a global research center in Barcelona focusing on this type of conditions, according to sources inside the company.

This will make the Catalan capital home to one of the five AstraZeneca research centers in the world, along with teams located in the United Kingdom, Sweden, the United States and Germany. The R&D center the company will open in Barcelona will bring together its own researchers and those from Almirall, for a total of 75 to 80 researchers. AstraZeneca highlights the excellent reputation of scientists working in Barcelona.

The company’s R&D center in Barcelona, located in 1,500 m2 that the company has leased in the Dau building, at the top end of Avinguda Diagonal, will focus on basic research into products in the respiratory field that will be taken to market in the short or long term.

AstraZeneca is a global biopharmaceutical company focused on developing and marketing prescription drugs, mainly to treat cardiovascular, respiratory, inflammatory, oncological and central nervous system diseases. They employ 51,700 people around the world in Europe (46%), America (28%) and Asia-Pacific (26%).

Share on networks

Related news

Llum verda a l’ampliació de l’aeroport del Prat: una inversió de 3.200 milions d’euros per assolir els 70 milions de passatgers

News

El Prat airport expansion gets green light: €3.2 billion to be invested to reach 70 million passengers

Barcelona, entre el ‘top cinc’ dels principals hubs de startups de la Unió Europea per segon any consecutiu

News

Barcelona among top five start-up hubs in European Union for second year in a row

El nou Campus Barcelona de Smith+Nephew consolida Catalunya com a referent de la innovació sanitària a Europa

News

New Smith+Nephew Barcelona Campus consolidates Catalonia as European benchmark in healthcare innovation

Les ciències de la vida a Catalunya es consoliden com a eix d’innovació i creixement: 220 milions d’inversió i 8,7% del PIB

News

Consolidation of life sciences in Catalonia as driving force for innovation and growth: €220 million invested and 8.7% of GDP

Barcelona Catalonia
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.